LENZ - LENZ Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$12.00
DETAILS
HIGH:
$12.00
LOW:
$12.00
MEDIAN:
$12.00
CONSENSUS:
$12.00
UPSIDE:
58.94%
About LENZ Therapeutics, Inc. (https://www.lenz-tx.com)
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Evert Schimmelpennink | President, Chief Executive Officer, Secretary & Director | 1972 | $1,242,200 USD |
| Marc G. Odrich | Chief Medical Officer | 1959 | $774,000 USD |
| Shawn Olsson | Chief Commercial Officer | 1983 | $724,600 USD |
| Daniel R. Chevallard | Chief Financial Officer | 1980 | $680,368 USD |
| James W. McCollum | Co-Founder & Director | 1955 | $40,000 USD |
| David Choromanski | Vice President of Marketing | – | – |
| Domenick Porfidia | Vice President of Sales | – | – |
| Kris Gambelin | Senior Vice President of Regulatory & Clincal Operations | – | – |
| Melissa Rosness | Senior Vice President of Manufacturing Operations | – | – |